Achieve life sciences awarded grant from the national institutes of health (nih) for the evaluation of cytisinicline in cessation of nicotine e-cigarette use

Seattle, wa and vancouver, bc / accesswire / july 22, 2021 / achieve life sciences, inc. (nasdaq:achv), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it has been awarded a grant from the national institute on drug abuse (nida) of the national institutes of health (nih) to evaluate the use of cytisinicline as a treatment for cessation of nicotine e-cigarette use. this initial grant award, to commence on august 1, 2021, will be utilized to complete critical regulatory and clinical operational activities, such as protocol finalization, clinical trial site identification, and submission of a new ind to fda for investigating cytisinicline in nicotine e-cigarette users.
ACHV Ratings Summary
ACHV Quant Ranking